Laboratories sourcing high-purity Hexarelin require verified peptide sequence integrity, stringent endotoxin limits, and transparent lot-specific analytical data. PX1 Research supplies USA-manufactured, research-grade Hexarelin (>99% purity) engineered specifically for in vitro assays, receptor binding studies, and preclinical growth hormone secretagogue research.
Laboratories sourcing high-purity Hexarelin require verified peptide sequence integrity, stringent endotoxin limits, and transparent lot-specific analytical data. PX1 Research supplies USA-manufactured, research-grade Hexarelin (>99% purity) engineered specifically for in vitro assays, receptor binding studies, and preclinical growth hormone secretagogue research.
Hexarelin injectable for sale from PX1 Research provides academic, institutional, and corporate laboratories with lyophilized, high-purity (>99%) His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Manufactured in US-based GMP-compliant facilities and verified by independent ISO 17025 accredited laboratories, each lot includes comprehensive RP-HPLC chromatograms, mass spectrometry reports, and quantitative endotoxin testing (<0.01 EU/mg) strictly for in vitro and preclinical research applications.
When evaluating suppliers offering research peptides for endocrine, cardiovascular, or receptor-binding experiments, analytical transparency is paramount. PX1 Research eliminates batch variability by ensuring that every vial of Hexarelin 5mg strictly adheres to chemical synthesis specifications, free from truncated sequences, TFA salts, or heavy metal contamination.
Hexarelin (chemically designated as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide derived from GHRP-6. Structurally, it incorporates D-amino acid substitutions that grant significantly enhanced enzymatic stability against circulating exopeptidases compared to native endogenous ghrelin. This structural resistance allows Hexarelin to maintain prolonged receptor interaction profiles in preclinical testing environments.
In vitro functional assays confirm that Hexarelin acts as a potent agonist at the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), a G-protein coupled receptor predominantly expressed in the anterior pituitary gland and hypothalamic nuclei. Activation of GHS-R1a by Hexarelin triggers the phospholipase C (PLC) signaling cascade, culminating in intracellular inositol trisphosphate (IP3) accumulation and rapid intracellular calcium ion mobilization.
Beyond its canonical GHS-R1a affinity, preclinical binding studies demonstrate that Hexarelin uniquely binds to CD36 (scavenger receptor class B member 1) expressed in cardiac tissue and vascular endothelium. This dual-receptor interaction profile distinguishes Hexarelin from simpler secretagogues and forms the basis of active investigation into non-endocrine, tissue-specific signaling pathways in rodent models.
Preclinical literature demonstrates that Hexarelin exhibits some of the highest intrinsic efficacy among first-generation hexapeptide secretagogues. In isolated rat pituitary cell culture models, exposure to Hexarelin induces dose-dependent secretion of somatotropin (growth hormone) without requiring synergism from endogenous Growth Hormone-Releasing Hormone (GHRH).
Animal model studies investigating pituitary-adrenal dynamics indicate that acute administration of Hexarelin yields rapid peak serum GH concentrations. However, extended exposure protocols in rodent and canine models demonstrate a characteristic tachyphylaxis or receptor desensitization. Researchers studying long-term GHS-R1a dynamics utilize Hexarelin specifically to analyze receptor downregulation kinetics, receptor recycling rates, and arrestin-mediated internalisation pathways.
Furthermore, in vitro cardiac assays employing isolated cardiomyocyte cultures have highlighted Hexarelin's CD36-mediated protective mechanisms against ischemic-reperfusion injury. These findings have prompted ongoing investigation within our research library hub regarding how GHS-R1a and CD36 co-activation influences cellular apoptosis, mitochondrial membrane potential, and calcium handling during hypoxic stress.
To select the appropriate tool for secretagogue modeling, researchers must understand the functional differences across peptide classes. Hexarelin exhibits distinct binding affinity, desensitization rates, and secondary receptor cross-reactivity when compared to second-generation agonists or GHRH derivatives.
Compared to Ipamorelin, which is recognized for its high selectivity for GHS-R1a without elevating ACTH or cortisol in vitro, Hexarelin displays significantly higher acute potency but demonstrates a broader signaling footprint and faster receptor desensitization. Conversely, relative to classic secretagogues like GHRP-6, Hexarelin incorporates specific chemical modifications that enhance chemical stability while eliminating ghrelin-induced appetite-stimulating pathway signaling in specific central nervous system assays.
When evaluating non-ghrelin pathways, researchers frequently pair GHS-R1a agonists with GHRH analogs such as CJC-1295 No DAC or Sermorelin. While GHRH analogs act via the adenylate cyclase/cAMP pathway, Hexarelin acts through the IP3/calcium signaling cascade. Co-incubating pituitary cells with both classes allows researchers to study synergistic intracellular cross-talk and maximal secretagogue response limits.
In cell culture work and preclinical animal models, biological variability must not be compounded by peptide impurities or bacterial endotoxins. Industrial synthesis of Hexarelin can generate truncated peptide fragments, residual coupling reagents, or excess trifluoroacetic acid (TFA) salts if purification protocols are inadequate.
PX1 Research enforces stringent quality control measures for every lot of Hexarelin injectable for sale. Every batch undergoes rigorous Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity exceeding 99.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) is simultaneously performed to verify the exact molecular mass (887.04 Da) and ensure correct amino acid sequencing without unexpected structural adducts.
Critically for preclinical research involving cell culture viability or animal administration, PX1 Research subjects all peptide lots to Chromogenic Reagent LAL (Limulus Amebocyte Lysate) assays to verify endotoxin levels below 0.01 EU/mg. Complete, unedited Certificate of Analysis (COA) documents detailing HPLC profiles, MS spectra, and endotoxin figures are available for download prior to purchase.
Hexarelin is supplied as a lyophilized (freeze-dried) powder in sealed, sterile glass vials to ensure long-term chemical stability. Proper reconstitution technique is vital to preserve the physical structure of the peptide hexamer and maintain uniform molar concentration across experimental runs.
Reconstitution should be conducted in a laminar flow hood using sterile laboratory technique. Recommended diluents include standard laboratory-grade 0.9% Bacteriostatic Sodium Chloride (containing 0.9% benzyl alcohol) or Sterile Water for Injection, depending on assay tolerance to antimicrobial agents. Diluent should be introduced slowly down the interior wall of the glass vial to prevent turbulent foaming and mechanical shearing of the peptide matrix.
Once the solvent contact is made, gentle swirling of the vial is recommended until complete dissolution occurs. Vortexing or violent shaking must be avoided, as atmospheric cavitation can induce peptide aggregation or denaturation. Reconstituted stock solutions should be aliquoted into low-protein-binding microcentrifuge tubes to prevent adsorption loss during repeated sampling.
Lyophilized Hexarelin exhibits high stability when maintained under controlled storage parameters. Upon receipt at the research facility, desiccated lyophilized vials should be stored in a sub-zero freezer environment at -20°C to -80°C for long-term storage (up to 24 months). Under these conditions, structural degradation and peptide hydrolysis are minimized.
Following reconstitution, liquid Hexarelin stock solutions must be refrigerated at 2°C to 8°C and protected from light exposure. Under refrigerated conditions, reconstituted solutions remain stable for experimental use for up to 28 days. Avoid repeated freeze-thaw cycles of reconstituted liquid solutions, as ice crystal formation can disrupt peptide bonds and cause loss of bioactivity.
If work requires micro-molar dilutions in aqueous culture media, working dilutions should be prepared immediately prior to assay execution to prevent hydrolytic cleavage in non-buffered room-temperature environments.
Research timelines require dependable supplier logistics and transparent manufacturing protocols. Off-shore peptide suppliers often present risks of customs delays, unverified manufacturing environments, and cold-chain integrity failures during international transit.
PX1 Research manufactures all compounds within ISO 9001 and GMP-compliant facilities located exclusively in the United States. Logistics operations are dispatched directly from fulfillment centers in California and Arizona. Orders placed Monday through Friday before 3:00 PM EST ship the same day, utilizing temperature-controlled, secure packaging to ensure that lyophilized integrity is maintained throughout transit.
For academic departments, contract research organizations (CROs), and institutional labs requiring larger material volumes or consistent lot numbers across multi-phase studies, PX1 Research provides dedicated support through our wholesale lab account portal, ensuring priority lot reservation and batch consistency.
All products sold by PX1 Research, including Hexarelin, are strictly designated for laboratory research use only (RUO), in vitro testing, and preclinical animal investigations. Hexarelin is not a pharmaceutical drug, medical device, or consumer supplement.
This compound is explicitly not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary diagnostic, therapeutic, prophylactic, or clinical applications. Under no circumstances should Hexarelin purchased from PX1 Research be administered to humans, introduced into food chains, or utilized for clinical diagnostic procedures. Adherence to these guidelines is mandatory for all institutional buyers.
What is the molecular weight and sequence of Hexarelin?
Hexarelin is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and a theoretical molecular weight of 887.04 g/mol.
What primary receptors does Hexarelin target in research models?
Hexarelin primarily acts as a high-affinity agonist at the Growth Hormone Secretagogue Receptor 1a (GHS-R1a) and also binds selectively to the scavenger receptor CD36.
How is purity verified for Hexarelin at PX1 Research?
Every lot undergoes independent ISO 17025 laboratory testing utilizing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm >99% purity and Electrospray Ionization Mass Spectrometry (ESI-MS) for structural identity verification.
What are the endotoxin limits for PX1 Research Hexarelin?
PX1 Research mandates that every batch of Hexarelin maintains endotoxin levels below 0.01 EU/mg, as quantified by LAL assay testing to prevent pyrogenic interference in cell and animal assays.
How should lyophilized Hexarelin be stored upon arrival?
Lyophilized vials should be stored in a dry environment at -20°C to -80°C for long-term stability. Avoid exposure to ambient heat, moisture, and direct light.
What solvent is recommended for reconstituting Hexarelin for in vitro assays?
Reconstitution is typically performed using sterile 0.9% Bacteriostatic Water or sterile phosphate-buffered saline (PBS), depending on the requirements of the specific cell culture or assay system.
How does Hexarelin compare in potency to Ipamorelin?
Preclinical assays show Hexarelin exhibits higher acute stimulation of GHS-R1a and faster peak GH release than Ipamorelin, though Hexarelin demonstrates faster receptor desensitization over sustained exposure.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research peptides are manufactured in US GMP-compliant facilities and shipped directly from dual distribution centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.